4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

43 library items in 4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

4: Central nervous system (remove) , 4.5 Drugs used in the treatment of obesity (remove) , 4.5.1 Anti-obesity drugs acting on the gastro-inte (remove)

Sort by: Display summary:

Results 1 - 10 of 43

Result page:
Previous
|
1
2
3
4
5
|
Next

1.

European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines

Source: EMA,
Date published: 17/02/2012

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | Adverse Drug Reactions | European Agency for the Evaluation of Medicinal Products (EMEA) | Liver disease | Obesity

NeLM Area:

News

Press release

Previous NeLM news report
2.

Stock shortages of Xenical® 120mg caps and Mircera® Pre-filled Syringe

Source: PSNC,
Date published: 01/02/2012

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Drug shortages

NeLM Area:

News

Link
3.

Anticipated orlistat (Xenical®) 120mg stock shortage

Source: PSNC (Pharmaceutical Services Negotiating Committee),
Date published: 13/01/2012

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | Drug shortages | Obesity

NeLM Area:

News

Link
4.

Is there an interaction between orlistat and levothyroxine?

Source: Regional Drug and Therapeutics Centre,
Date published: 10/01/2012
Review date: 31/01/2014

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | 6.2.1 Thyroid hormones | Drug Interactions

NeLM Area:

Evidence > Medicines Q & A

Is there an interaction between orlistat and levothyroxine?
5.

Over-the-counter orlistat: early experiences, views and attitudes of community pharmacists in Great Britain

Source: International Journal of Clinical Pharmacy,
Date published: 27/07/2011

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | Community pharmacy | OTC medicines

NeLM Area:

Evidence > Medicines Management > References

Abstract link
6.

Public Citizen sends petition to FDA requesting removal of orlistat products (Alli and Xenical) from the market

Source: PharmaLive,
Date published: 18/04/2011

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | Adverse Drug Reactions | Food &Drug Administration (FDA) | Liver disease | Obesity | Renal medicine | Risk management

NeLM Area:

News

Link to PharmaLive report

Link to Inpharm report

Link to NeLM report
7.

Research letter: Orlistat and acute kidney injury

Source: Archives of Internal Medicine,
Date published: 12/04/2011

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | Adverse Drug Reactions | Obesity | Renal medicine

NeLM Area:

News

Link (extract)
8.

NPCi Blog: Are NICE recommendations about monitoring patients on orlistat being followed?

Source: NPC,
Date published: 03/12/2010

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | Clinical guidelines | National Institute of Clinical Excellence (NICE) | Obesity | Prescribing and supply of medicines

NeLM Area:

News

Link
9.

FDA drug safety communication: Completed safety review of Xenical®/Alli® (orlistat) and severe liver injury

Source: FDA,
Date published: 27/05/2010

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | Adverse Drug Reactions | Food &Drug Administration (FDA) | Liver disease | Product Licence Changes

NeLM Area:

News

FDA release

FDA MedWatch information

Previous NeLM news report (MHRA Drug Safety Update)
10.

Treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials

Source: DARE,
Date published: 29/03/2010

Category:

4.5.1 Anti-obesity drugs acting on the gastro-intestinal tract | 4.5.2 Centrally acting appetite suppressants | Obesity | Paediatrics

NeLM Area:

Evidence > Disease Focused Reviews

DARE abstract

Results 1 - 10 of 43

Result page:
Previous
|
1
2
3
4
5
|
Next